Y 90 Ibritumomab Tiuxetan &Rituximab Relapsed or Refractory Diffuse Large B-Cell Non-Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma, including any of the following:
• * B-cell diffuse large cell variant
• * Immunoblastic
• * Mediastinal (thymic) large cell
• * T-cell/histiocyte-rich
• * Anaplastic large B-cell
• * Intravascular large B-cell
• * Lymphomatoid granulomatosis
• Relapsed or refractory disease after at least 1 prior chemotherapy regimen and requires further treatment
• * Relapsed disease, defined as the following:
• * Appearance of any new lesion OR increase of at least 50% in the size of a previously involved site
• * 50% increase in greatest diameter of any previously identified node greater than 1 cm in the short axis OR in the sum of the perpendicular diameter (SPD) of more than 1 node
• * Progressive disease, defined as the following:
• * 50% increase from nadir in the SPD of any previously identified abnormal node
• * Appearance of any new lesion during or at the end of therapy
• CD20-positive disease by immunohistochemistry
• Bidimensionally measurable disease
• * At least 1 lesion at least 2.0 cm by CT scan
• Less than 25% bone marrow involvement by lymphoma
• No transformed lymphoma from indolent to aggressive
• No HIV- or AIDS-related lymphoma
• No hypocellular bone marrow
• No marked reduction in bone marrow precursors of 1 or more cell lines (e.g., granulocytic, megakaryocytic, or erythroid)
• No CNS lymphoma
• Ineligible for myeloablative therapy OR refused transplantation
• Ineligible for any other open yttrium Y 90 ibritumomab tiuxetan investigational protocols
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Performance status
• WHO 0-2
• Life expectancy
• At least 3 months
• Hematopoietic
• Absolute neutrophil count at least 1,500/mm\^3
• Lymphocyte count no greater than 5,000/mm\^3 (for patients with small lymphocytic lymphoma)
• Platelet count at least 100,000/mm\^3
• Hepatic
• Bilirubin no greater than 2.0 mg/dL
• Renal
• Creatinine no greater than 2.0 mg/dL
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 1 year after study participation
• No concurrent serious nonmalignant disease or infection that would preclude study participation
• No human antimurine antibody reactivity
• PRIOR CONCURRENT THERAPY:
• Biologic therapy
• See Disease Characteristics
• No prior autologous bone marrow transplantation
• No prior peripheral blood stem cell rescue
• No prior failed stem cell collection
• Prior rituximab within the past 90 days allowed provided patient has fludeoxyglucose-avid disease that is also indium In 111 ibritumomab tiuxetan-avid disease in at least 1 lesion
• More than 2 weeks since prior filgrastim (G-CSF) or sargramostim (GM-CSF)
• Chemotherapy
• See Disease Characteristics
• Endocrine therapy
• Not specified
• Radiotherapy
• No prior radioimmunotherapy
• No prior external beam radiotherapy (involved field or regional) to more than 25% of active bone marrow
• Surgery
• More than 4 weeks since prior major surgery (except diagnostic surgery)
• Other
• Recovered from all prior therapy
• More than 4 weeks since prior therapy for lymphoma
• More than 8 weeks since prior phase II investigational drugs
• No other concurrent antineoplastic therapy